IR Biosciences Holdings Inc.
OTC: IRBS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chet Leach D.A.B.T.
- Employees
- 4
- Headquarters
- Scottsdale, United States
- IPO year
- 2023
- Market cap
- $128.1K
Loading IRBS…
Loading profile data…Frequently asked questions about IRBS
What does IR Biosciences Holdings Inc. (IRBS) do?
IR BioSciences Holdings, Inc. is a U.S.-based, early-stage biotechnology firm. Through its subsidiary, ImmuneRegen BioSciences, Inc., it concentrates on researching and developing therapies for significant health challenges, including pulmonary fibrosis, influenza infections, and neutropenia caused by radiation. The company is also actively deve...
Where does IRBS trade?
IR Biosciences Holdings Inc. (IRBS) trades on the Other OTC.
What sector is IRBS in?
IR Biosciences Holdings Inc. (IRBS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of IR Biosciences Holdings Inc.?
Chet Leach D.A.B.T. is the chief executive officer of IR Biosciences Holdings Inc. (IRBS).
Where is IR Biosciences Holdings Inc. headquartered?
IR Biosciences Holdings Inc. is headquartered in United States.
Does IRBS pay a dividend?
IR Biosciences Holdings Inc. (IRBS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IRBS go public?
IR Biosciences Holdings Inc. (IRBS) completed its initial public offering in 2023.